Stocktoria
DYADIC INTERNATIONAL INC DYAI
DYADIC INTERNATIONAL INC (DYAI) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $3.1M at a -238.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DYAI | DYADIC INTERNATIONAL INC | 1/9 | — | — | — |
| SRZN | Surrozen, Inc./DE | 2/9 | -15.54 | — | -67.4% |
| CRSP | CRISPR Therapeutics AG | 1/9 | 6.42 | — | -90.6% |
| ALGS | Aligos Therapeutics, Inc. | 2/9 | — | — | — |
| CGON | CG Oncology, Inc. | 2/9 | — | — | — |
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
| OCGN | Ocugen, Inc. | 2/9 | — | — | — |
About DYADIC INTERNATIONAL INC
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
FAQ
Is DYAI financially healthy?
DYADIC INTERNATIONAL INC's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does DYAI pay a dividend?
No, DYADIC INTERNATIONAL INC does not currently pay a dividend.
How profitable is DYAI?
In FY2025, DYADIC INTERNATIONAL INC had a net margin of -238.3% and a return on equity of -597.6%.
What is the analyst price target for DYAI?
The average Wall-Street price target for DYADIC INTERNATIONAL INC is $6.00, about 581.8% above the recent price, from 2 analysts.
Is DYAI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DYADIC INTERNATIONAL INC: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.